Monetary giants have made a conspicuous bearish transfer on Amgen. Our evaluation of choices historical past for Amgen AMGN revealed 13 uncommon trades.
Delving into the small print, we discovered 46% of merchants have been bullish, whereas 53% confirmed bearish tendencies. Out of all of the trades we noticed, 10 have been places, with a price of $1,065,054, and three have been calls, valued at $142,121.
Projected Value Targets
Analyzing the Quantity and Open Curiosity in these contracts, it appears that evidently the massive gamers have been eyeing a value window from $140.0 to $470.0 for Amgen through the previous quarter.
Analyzing Quantity & Open Curiosity
By way of liquidity and curiosity, the imply open curiosity for Amgen choices trades in the present day is 326.67 with a complete quantity of 602.00.
Within the following chart, we’re in a position to observe the event of quantity and open curiosity of name and put choices for Amgen’s huge cash trades inside a strike value vary of $140.0 to $470.0 over the past 30 days.
Amgen 30-Day Possibility Quantity & Curiosity Snapshot
Largest Choices Noticed:
| Image | PUT/CALL | Commerce Kind | Sentiment | Exp. Date | Ask | Bid | Value | Strike Value | Complete Commerce Value | Open Curiosity | Quantity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BULLISH | 01/17/25 | $58.55 | $56.95 | $58.2 | $320.00 | $232.8K | 1.0K | 112 |
| AMGN | PUT | SWEEP | BULLISH | 01/17/25 | $58.25 | $57.0 | $58.2 | $320.00 | $174.6K | 1.0K | 112 |
| AMGN | PUT | SWEEP | BEARISH | 01/17/25 | $57.95 | $57.95 | $57.95 | $320.00 | $173.8K | 1.0K | 0 |
| AMGN | PUT | SWEEP | BEARISH | 01/17/25 | $57.9 | $57.9 | $57.9 | $320.00 | $162.1K | 1.0K | 32 |
| AMGN | PUT | TRADE | NEUTRAL | 01/17/25 | $58.95 | $56.65 | $57.9 | $320.00 | $69.4K | 1.0K | 72 |
About Amgen
Amgen is a frontrunner in biotechnology-based human therapeutics. Flagship medication embody pink blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory illnesses. Amgen launched its first most cancers therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (authorized 2010) and Evenity (2019). The acquisition of Onyx bolstered the agency’s therapeutic oncology portfolio with Kyprolis. Current launches embody Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung most cancers), and Tezspire (bronchial asthma). The 2023 Horizon acquisition brings a number of uncommon illness medication, together with thyroid eye illness drug Tepezza. Amgen additionally has a rising biosimilar portfolio.
In gentle of the latest choices historical past for Amgen, it is now acceptable to concentrate on the corporate itself. We purpose to discover its present efficiency.
Amgen’s Present Market Standing
- With a buying and selling quantity of 528,508, the worth of AMGN is down by -0.79%, reaching $267.86.
- Present RSI values point out that the inventory is is at the moment impartial between overbought and oversold.
- Subsequent earnings report is scheduled for 20 days from now.
Choices buying and selling presents greater dangers and potential rewards. Astute merchants handle these dangers by frequently educating themselves, adapting their methods, monitoring a number of indicators, and preserving an in depth eye on market actions. Keep knowledgeable in regards to the newest Amgen choices trades with real-time alerts from Benzinga Professional.
